Researchers are gaining a dynamic lens into a tumor's molecular response to therapeutic pressure. As these data are combined with modern ML, how might cancer trial design evolve over this decade?
I'm really excited that adaptive trial design is finally getting noticed instead of being a niche topic that only elite cancer trialists get excited about.
They hope to spur development of adaptive biomarkers for evolving metastatic cancers with the kind of trial design that ought to be the gold standard for precision medicine.
I'm really excited that adaptive trial design is finally getting noticed instead of being a niche topic that only elite cancer trialists get excited about.
Have you seen the new program from ARPA-H?
https://arpa-h.gov/research-and-funding/programs/adapt
They hope to spur development of adaptive biomarkers for evolving metastatic cancers with the kind of trial design that ought to be the gold standard for precision medicine.
Really enjoyed reading + love the clinical context of the ctDNA seq advancement.